Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA)
Summary
Kura Oncology, Inc. buy thesis: ziftomenib AML launch, strong combo trial data, $660M liquidity and runway, and menin inhibitor competition. Click for this upda...
Description
Kura Oncology, Inc. buy thesis: ziftomenib AML launch, strong combo trial data, $660M liquidity and runway, and menin inhibitor competition. Click for this upda...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source